Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 8/20 | 0.80 |
| ▸ | CDC25B | P30305 | 6/20 | 0.80 |
| ▸ | GPBAR1 | Q8TDU6 | 7/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.46 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14446939 | 0.96 | CDC25A (0.78) | CDC25ACDC25BGPBAR1NR1H4NPC1L1 | |
| SCHEMBL9010584 | 0.91 | CDC25A (0.74) | CDC25ACDC25BGPBAR1NR1H4 | |
| SCHEMBL12153482 | 0.89 | CDC25A (1.00) | CDC25ACDC25BNPC1L1 | |
| SCHEMBL9558404 | 0.89 | CDC25A (1.00) | CDC25ACDC25BNPC1L1 | |
| SCHEMBL9121941 | 0.89 | CDC25A (1.00) | CDC25ACDC25BNPC1L1 | |
| SCHEMBL9883787 | 0.87 | CDC25A (0.78) | CDC25ACDC25BGPBAR1NR1H4NPC1L1 | |
| SCHEMBL13777440 | 0.87 | CDC25A (0.82) | CDC25ACDC25BGPBAR1NR1H4NPC1L1 | |
| SCHEMBL14261167 | 0.87 | CDC25A (0.78) | CDC25ACDC25BGPBAR1NR1H4NPC1L1 | |
| SCHEMBL12190432 | 0.87 | CDC25A (0.78) | CDC25ACDC25BGPBAR1NR1H4NPC1L1 | |
| SCHEMBL9010519 | 0.86 | CDC25A (0.76) | CDC25ACDC25BGPBAR1NR1H4NPC1L1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440647-B2 | 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-05-14 | — | — | US | disclosed |
| US-8440647-B2 | 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130018021-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018021-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2013-01-17 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-8188064-B2 | Reducing cell differentiation of adipocyte; reducing body fat | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-05-29 | — | — | US | disclosed |
| US-7713952-B2 | 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-05-11 | — | — | US | disclosed |
| US-20070270391-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION, A NON-STOCK, NON-PROFIT WISCONSIN CORPORATION (US) | 2007-11-22 | — | — | US | disclosed |
| US-20070249567-A1 | 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249567-A1 | 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-10-25 | — | — | US | disclosed |
| US-7244719-B2 | 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-7241749-B2 | 2α-Methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and their uses | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270391-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | CYP24A1, CYP27B1, CD14 | CDC25A 399/4885CDC25B 520/4885GPBAR1 2257/4885 |
| US-20130018021-A1 | 2Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses | CYP24A1, CYP27B1, CD14 | CDC25A 399/4885CDC25B 520/4885GPBAR1 2257/4885 |
| US-20070249567-A1 | 2-Methylene-19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Its Uses | CYP27B1, CYP24A1, VDR | CDC25A 980/4885CDC25B 1218/4885GPBAR1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.